Has Kourtney Russo received payments from drug or device companies?

Yes. Drug and device makers reported $9,523 in general payments to Kourtney Russo across 316 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kourtney Russo did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kourtney Russo come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kourtney Russo

Family · Fort Worth, TXNPI 1487207031

Payments from drug & device makers

$9,523in general payments, 2019–2025

Across 316 payments — averaging $30.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$1K
Epizyme, Inc.$690
AstraZeneca$614
GSK$607
E.r. Squibb & Sons, L.L.C.$472
AbbVie$376
plus $6K from 51 others

What the payments were for

Speaking & faculty fees$4955%
Food & beverage$8,92894%
Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	53	$1,153
Epizyme, Inc.	9	$690
AstraZeneca(2 entities)	20	$614
GSK	29	$607
E.r. Squibb & Sons, L.L.C.	6	$472
AbbVie	13	$376
Johnson & Johnson(2 entities)	9	$376
Gilead(2 entities)	9	$352
Adaptive Biotechnologies Corporation	13	$302
Sobi, Inc	8	$290
Incyte Corporation	8	$284
Bristol Myers Squibb	13	$282
Takeda Pharmaceuticals U.S.A., Inc.	8	$180
Lilly USA, LLC	8	$168
Stemline Therapeutics Inc.	3	$164
Novartis	7	$163
Eisai Inc.	6	$158
Regeneron Healthcare Solutions, Inc.	5	$157
Pharmaessentia USA Corporation	4	$151
Pharmacosmos Therapeutics Inc.	2	$148
Merck	6	$148
Sirtex Medical Inc	1	$147
Blueprint Medicines Corporation	2	$140
ADC Therapeutics America, Inc.	2	$137
Puma Biotechnology, Inc.	1	$136
Tempus AI, Inc	3	$131
Sanofi	5	$131
Genmab U.S., Inc.	5	$116
Beigene USA, Inc.	4	$95
Pfizer	4	$86
TG Therapeutics, Inc.	3	$85
Morphosys, US Inc.	4	$80
Bard Peripheral Vascular, Inc.	1	$73
Servier Pharmaceuticals LLC	3	$73
Geron Corporation	3	$71
Karyopharm Therapeutics Inc.	3	$66
Agios Pharmaceuticals, Inc.	2	$65
Amgen	2	$57
Taiho Oncology, Inc.	3	$55
Exelixis Inc.	2	$53
Tactile Systems Technology Inc	3	$51
Bayer	2	$46
Genentech USA, Inc.	2	$46
Caris MPI, Inc.	2	$42
Astellas Pharma US Inc	2	$39
Kyowa Kirin, Inc.	2	$33
Sun Pharmaceutical Industries Inc.	1	$31
Foundation Medicine, Inc.	1	$28
Coherus Oncology, Inc.	1	$27
Array Biopharma Inc	1	$27
Apellis Pharmaceuticals, Inc.	1	$24
Immunocore Limited	1	$22
Seagen Inc.	1	$17
Aimmune Therapeutics, Inc.	1	$16
Iovance Biotherapeutics, Inc.	1	$14
Boehringer Ingelheim	1	$14
Clovis Oncology, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,523 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XareltoRivaroxaban	25	$23,427
EliquisApixaban	24	$19,407
Megestrol Acetate	41	$1,972
Prochlorperazine Maleate	51	$908
Ondansetron OdtOndansetron	69	$809
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine	28	$716
Pantoprazole Sodium	49	$474
Nystatin	20	$370
Acyclovir	29	$351
Dexamethasone	11	$286
Hydroxyurea	14	$259
Hydrocortisone	16	$236
Potassium Chloride	23	$207
Prednisone	31	$182
Gabapentin	20	$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonXarelto	$376	$23,42725 claims
PfizerEliquis	$86	$19,40724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Fort Worth

Laura MoeFort Worth$158K
Julie TaylorFort Worth$63K
Ryan BourgeoisFort Worth$37K
Lashonda CraneHouston$3.4M
David WeirDallas$959K
Luba YammineHouston$479K
Robin BeachHouston$428K
Nirupama JeromeAustin$418K
April LopezMcAllen$417K
Linda MercadoHouston$211K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →